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Background: In Germany, annual vaccination against seasonal influenza is recommended for certain target groups
(e.g. persons aged ≥60 years, chronically ill persons, healthcare workers (HCW)). In season 2009/10, vaccination
against pandemic influenza A(H1N1)pdm09, which was controversially discussed in the public, was recommended
for the whole population. The objectives of this study were to assess vaccination coverage for seasonal (seasons
2008/09-2010/11) and pandemic influenza (season 2009/10), to identify predictors of and barriers to pandemic
vaccine uptake and whether the controversial discussions on pandemic vaccination has had a negative impact on
seasonal influenza vaccine uptake in Germany.
Methods: We analysed data from the ‘German Health Update’ (GEDA10) telephone survey (n=22,050) and a smaller
GEDA10-follow-up survey (n=2,493), which were both representative of the general population aged ≥18 years
living in Germany.
Results: Overall only 8.8% of the adult population in Germany received a vaccination against pandemic influenza.
High socioeconomic status, having received a seasonal influenza shot in the previous season, and belonging to a
target group for seasonal influenza vaccination were independently associated with the uptake of pandemic
vaccines. The main reasons for not receiving a pandemic vaccination were ‘fear of side effects’ and the opinion that
‘vaccination was not necessary’. Seasonal influenza vaccine uptake in the pre-pandemic season 2008/09 was 52.8%
among persons aged ≥60 years; 30.5% among HCW, and 43.3% among chronically ill persons. A decrease in
vaccination coverage was observed across all target groups in the first post-pandemic season 2010/11 (50.6%,
25.8%, and 41.0% vaccination coverage, respectively).
Conclusions: Seasonal influenza vaccination coverage in Germany remains in all target groups below 75%, which is
a declared goal of the European Union. Our results suggest that controversial public discussions about safety and
the benefits of pandemic influenza vaccination may have contributed to both a very low uptake of pandemic
vaccines and a decreased uptake of seasonal influenza vaccines in the first post-pandemic season. In the upcoming
years, the uptake of seasonal influenza vaccines should be carefully monitored in all target groups to identify if this
trend continues and to guide public health authorities in developing more effective vaccination and
communication strategies for seasonal influenza vaccination.
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In Germany, annual influenza epidemics usually occur
during the winter months December to March. In the last
decade, an estimated zero to 19,000 excess deaths per year
were attributable to influenza virus infections [1]. More-
over, approximately one to six million influenza-related
excess physician consultations per season were estimated
for Germany [2]. Severe influenza virus infections or
influenza-related complications typically occur in the very
young and elderly population as well as in persons with
underlying chronic medical conditions.
Annual vaccination has proven to be an effective
method to reduce the burden of influenza disease [3]. In
Germany, vaccination against seasonal influenza is recom-
mended by the Standing Committee on Vaccination
(STIKO) for individuals who have either an increased risk
to develop severe influenza disease (i.e. persons aged ≥60
years, pregnant women, and persons with certain chronic
medical conditions) or who are likely to transmit the virus
to vulnerable groups (e.g. health care workers (HCW)) [4].
Vaccination is free of charge for the target groups in
Germany. During the influenza pandemic 2009/10,
STIKO additionally recommended vaccination with a
monovalent vaccine against the pandemic influenza virus
strain A(H1N1)pdm09 for the whole population. Due to
expected limitations in vaccine supplies at the beginning
of the vaccination campaign, STIKO defined and ranked
priority groups for the pandemic vaccination: 1) HCW, 2)
persons with underlying chronic conditions, 3) pregnant
women, 4) household contacts of vulnerable persons, 5)
all other persons aged 6 months to 24 years, 6) all other
persons aged 25–59 years, 7) all other person aged 60
years and above [5]. The pandemic vaccination campaign
started in Germany on 26 October 2009 [6]. The AS03-
adjuvanted monovalent vaccine PandemrixW was almost
exclusively used and available in sufficient quantities [7].
During the pandemic, vaccination against A(H1N1)
pdm09 was subject to controversial discussions, not only
in Germany but also in many other countries worldwide
[7-9]. Main topics of the debate in the media and among
experts and ‘self-proclaimed experts’ were vaccine safety,
effectiveness, and concern that there were too little data
on the new vaccines or vaccine ingredients (especially
new adjuvants) available. Moreover, the general necessity
of vaccination in view of the relative mildness of the
pandemic influenza disease was called into question
[7,9-11]. As a result, compliance with the national
recommendations for pandemic vaccination was very
poor in Germany. Since Germany has no central
immunization registry, information on vaccination
coverage (and factors influencing coverage) is only avail-
able from telephone and household surveys [12-15].
According to the results of thirteen consecutive cross-
sectional telephone surveys (total n=13,010) conductedduring the pandemic, only 8.1% of the general popula-
tion aged ≥14 years living in Germany received a vaccine
against pandemic influenza [6].
To develop target group specific communication strat-
egies and to enhance compliance with the official
recommendations it is important to monitor vaccine up-
take in each of the target groups and to understand fac-
tors that influence uptake. This applies not only for
annual influenza vaccination campaigns but also for the
planning of future vaccination campaigns during a pan-
demic. The influence of the 2009/2010 pandemic situation
on seasonal influenza vaccine uptake in Germany in the
post-pandemic seasons has so far not been investigated.
For this purpose, we utilized data from the large (~22,000
respondents) ‘German Health Update 2010’ (GEDA10)
telephone survey and a smaller GEDA10 follow-up survey
(~2,500 respondents). The objectives of our study were (1)
to assess seasonal influenza vaccination coverage for sea-
sons 2008/09 to 2010/11, (2) to assess pandemic influenza
vaccination coverage for season 2009/10, (3) to identify
predictors of and barriers to pandemic vaccine uptake,
and (4) to detect a potential influence of the pandemic
situation on seasonal influenza vaccine uptake in the first
post-pandemic season (2010/11).Methods
Study population and survey design
The GEDA survey design has been described previously
[12,13,16]. In brief, GEDA is a large annual telephone
survey which is conducted by the Robert Koch Institute
(RKI) as a part of Germany’s national health monitoring.
The study population consists of persons ≥18 years of
age who are living in a private household in Germany,
have sufficient knowledge of the German language, and
can be contacted via landline telephone. The GEDA
study protocol was approved by Germany’s federal and
regional data-protection commissioners. All data were
collected and analysed in an anonymous manner.
In this study we present data from GEDA10 which
was conducted between 22 September 2009 and 10 July
2010. Since the annual GEDA survey was not conducted
in 2010/2011, we conducted a follow-up interview
among a subsample of 2.493 GEDA10 respondents
(from now on referred to as the GEDA follow-up survey)
from 1 April to 2 July 2011 to assess seasonal influenza
vaccine uptake for the post pandemic season 2010/11.
Based on a sample size calculation, 385 subjects were
needed to estimate a prevalence of 50% (“worst case
scenario”) vaccine uptake with a confidence interval of
+/− 5%. Our sample size of ~2,400 subjects for the follow-
up survey was based on the premise to estimate a preva-
lence (i.e. vaccination coverage) of 50% for up to six sub-
groups (=cells; 6*385≈2400).
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ship of the data lies with RKI and we did not have to ob-
tain permission to use the data for this study. Similar to
the previous GEDA survey (GEDA09), a public use file
of the GEDA10 dataset will be provided soon. Data from
the GEDA follow-up survey will not be openly available.
To control for possible selection biases, weighting fac-
tors for the GEDA10 sample were constructed by taking
age, sex, educational status, geographical region, and
household size into consideration. Potential participants
of the follow-up survey were sampled disproportionally
to their weighting factors in GEDA10. We applied this
method to avoid that groups which were already under-
represented in GEDA10 become underrepresented again
at the sampling stage in the follow-up sample and thus
to prevent further bias. Weighting factors for the follow-
up survey were constructed in a first step on the basis of
the values calculated for GEDA10 (for age, sex, educa-
tion, adipositas, smoking status, subjective health, phys-
ical activity, employment status), and, in a second step,
on population data gathered in the Microcensus 2008
[17], taking geographical region, age, sex, and educa-
tional status into account.
Information on seasonal influenza vaccination status
for season 2008/2009 was collected from all participants
of GEDA10. Between 1 January 2010 and 10 July 2010
respondents were additionally asked to provide informa-
tion on seasonal and pandemic influenza vaccination
status for season 2009/10. Unvaccinated survey partici-
pants of GEDA10 were additionally asked to state their
reasons for not receiving a pandemic influenza vaccin-
ation. Information on seasonal vaccination status for
season 2010/11 was collected from all respondents of
the GEDA follow-up survey. In the follow-up survey,
respondents were additionally asked by whom they were
vaccinated (general practitioner/other physician in pri-
vate practice/occupational physician/other) and in which
month they received the vaccination against seasonal in-
fluenza in season 2010/11. One should note that
GEDA10 does not cover the paediatric population (aged
0–17 years) for which pandemic vaccination was also
recommended in Germany. Information on vaccination
coverage in this particular age-group was therefore not
available from this data source.
We calculated the response for GEDA10 by using Re-
sponse Rate 3 as defined by the American Association
for Public Opinion Research (AAPOR) [18]. Response
Rate 3 is the proportion of the number of complete
interviews divided by the number of interviews plus the
number of non-interviews (refusal and break-off plus
non-contacts plus others) plus cases of unknown eligibil-
ity. For cases of unknown eligibility Response Rate 3
estimates what proportion of cases of unknown eligibil-
ity is actually eligible. This estimation is based on theproportion of eligible households among all numbers for
which a definitive determination of status was obtained
(hence a very conservative estimate). We additionally
calculated the cooperation rate at respondent level,
which is defined as the proportion of all respondents
interviewed of all respondents ever contacted [18]. Since
the GEDA follow-up survey was not a random digit dial-
ling study (as GEDA10), we reported the minimal re-
sponse rate (Response Rate 1 as defined by AAPOR,
[18]) for the follow-up survey.Definition of variables
Socio-economic status levels were created as described
by Lampert and Kroll on the basis of self-reported edu-
cational, income, and professional status of survey
respondents [19]. In accordance with the STIKO-
recommendations [4], persons were classified into the
target groups for seasonal influenza vaccination in our
study if they reported (1) to be ≥60 years of age, (2) to
have at least one underlying chronic disease (defined
here as having a chronic underlying respiratory, cardio-
vascular, liver, or renal disease, cancer, or diabetes), or
(3) to work as HCW. Since female respondents of child-
bearing age were not asked whether they had been preg-
nant during the last influenza season, it was not possible
to include pregnant women as target group in our ana-
lysis. The geographic region category ‘Western Federal
States’ (WFS) comprised the federal states Schleswig-
Holstein, Bremen, Hamburg, Lower Saxony, Hesse,
Rhineland-Palatinate, Saarland, North Rhine-Westphalia,
Baden-Württemberg and Bavaria; ‘Eastern Federal
States’ (EFS) comprised Mecklenburg-Vorpommern,
Brandenburg, Berlin, Saxony-Anhalt, Thuringia and
Saxony.Statistical analysis
Data analysis was performed using PASW 18.0 for
Windows (SPSS Inc., Chicago, USA). Proportions were
calculated by using procedures for the analysis of com-
plex samples. Univariate analyses were conducted to
determine associations between pandemic influenza vac-
cine uptake and socio-demographic, health-related and
professional factors. A p-value ≤0.05 was considered to
indicate a statistically significant difference. Odds ratios
(OR) and 95% confidence intervals (CI) were calculated
as appropriate. Multivariable analysis was performed by
entering variables potentially associated with vaccine up-
take (p-value <0.2 in univariate analysis) into a multi-
variable logistic regression model in a first step, followed
by step-wise backward removal of variables with a
p-value >0.05 to produce a final model. Interaction
terms were included to account for effect modification
between independent variables.
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Sample characteristics
In total, 22,050 telephone interviews were conducted dur-
ing the study period of GEDA10 and 2,493 participants
were re-interviewed for the follow-up survey. An overview
of the survey populations is given in Table 1. The median
age was 48.0 years (range 18–99 years) in GEDA10 and
49.7 years (range 19–96 years) in the follow-up survey. Re-
sponse Rate 3 was 28.9% in GEDA10; the cooperation rate
at respondent level was 55.8%. Response Rate 1 was 75.0%
in the follow up survey.
Seasonal influenza vaccination coverage
Information on seasonal influenza vaccination status was
available for over 99.8% in each of the study samples for
the three seasons under investigation (seasons 2008/09-
2010/11). Vaccination coverage for the three seasons by
sex, age group, place of residence, and target group is
presented in Table 2. To allow comparability with inter-
national studies, seasonal influenza vaccine uptake
among ≥65 year-olds was additionally calculated and
revealed a coverage of 56.1% (95% CI: 54.0-58.2) in sea-
son 2008/09, 50.2% (95% CI: 47.5-52.9) in season 2009/
10, and 54.2% (95% CI: 48.4-59.8) in season 2010/11. For
influenza season 2009/10, vaccination coverage was cal-
culated by age-groups in decades (Figure 1). Vaccine up-
take in both the target population for seasonal influenzaTable 1 Characteristics of participants in the ‘German







April – July 2011
n* %* n* %*
Total 22,050 100 2,493 100
Sex
female 11,347 51.5 1,287 51.6
male 10,703 48.5 1,206 48.4
Age group
18-39 years 7,145 32.4 761 30.5
40-59 years 8,142 36.9 937 37.6
≥60 years 6,763 30.7 795 31.9
Place of residence
Western Federal States 17,433 79.1 1,968 79.0
Eastern Federal States 4,617 20.9 525 21.0
Underlying chronic disease
yes 7,260 32.9 972 39.0
no 14,790 67.1 1,521 61.0
Health care worker
yes 1,117 5.1 225 9.0
no 20,933 94.9 2,268 91.0
*Weighted data.vaccination (defined here as persons who have an under-
lying chronic disease, or work as HCW) and non-target
population increased with age and was highest in per-
sons ≥70 years. The vast majority (97.8%) of vaccinated
persons had received their influenza vaccination for sea-
son 2010/11 by the end of December 2010.
Figure 2 shows trends in seasonal influenza vaccine
uptake among the three different target groups and the
non-target group for four consecutive seasons (2007/08
to 2010/11; results for season 2007/08 according to a
previously published analysis of GEDA 2009 data [12]).
While vaccination coverage slightly decreased in persons
aged ≥60 years and in persons with underlying chronic
diseases between seasons 2007/08 and 2009/10, there
was an increase in vaccine uptake among HCWs from
season 2007/08 to 2008/09. In all subgroups under in-
vestigation, vaccine uptake for season 2009/10 was
higher in the follow-up sample (empty symbols) com-
pared to the GEDA10 sample (filled symbols). Consider-
ing only the results from the follow-up survey (Figure 2),
a significant decrease in seasonal influenza vaccination
coverage between seasons 2009/10 and 2010/11 was
observed for persons with underlying chronic conditions
(p=0.04), HCWs (p=0.03), and persons not targeted for
seasonal influenza vaccination (p<0.01). For persons ≥60
years of age there was also a decrease, but without
reaching statistical significance. In season 2010/11,
83.4% of respondents who received a seasonal influenza
shot were vaccinated by their general practitioner, 4.7%
by another physician in private practice (e.g. gynaecolo-
gist, paediatrician), 9.4% by an occupational physician,
0.4% by a hospital physician, and 2.1% by any other
physician. Of those who were vaccinated by a general
practitioner or by an occupational physician, 18.4% and
59.4% did not belong to a target group, respectively.
Pandemic influenza vaccination coverage
Information on pandemic influenza vaccine uptake was
available for 99.9% of the respective study population in
GEDA 10 (n=13,048). Vaccination coverage by sex, age
group, place of residence, socio-economic status and differ-
ent target groups for seasonal influenza vaccination is pre-
sented in Table 3. In total, 8.8% (95% CI: 8.2-9.5) of the
general adult population in Germany received a vaccination
against pandemic influenza. With 11.2% (95% CI: 10.2-12.3)
pandemic vaccine uptake was significantly higher in per-
sons belonging to the target group for seasonal influenza
vaccination as compared to the non-seasonal influenza tar-
get group (6.4%; 95% CI: 5.7-7.1; p<0.001).
The most frequently reported reasons for not receiving
the vaccination were (1) ‘fear of side effects of pandemic
vaccines’ (stated by 37.2%; 95% CI: 36.1-38.3), (2) ‘pandemic
vaccination is not necessary’ (33.8%; 95% CI: 32.7-34.9),
(3) ‘pandemic vaccination not officially recommended
Table 2 Seasonal influenza vaccine uptake by sex, age group, place of residence and target group,
seasons 2008/09 − 2010/11, Germany
Season 2008/09 Season 2009/10 Season 2010/11
n=22,009 % (95% CI)* n=13,040 % (95% CI)* n=2,492 % (95% CI)*
Total 29.8 (29.0-30.6) 26.6 (25.6-27.6) 28.3 (26.0-30.6)
Sex
female 30.8 (29.7-31.9) 27.2 (25.8-28.6) 28.2 (25.3-31.3)
male 28.8 (27.6-30.0) 26.0 (24.5-27.5) 28.3 (25.0-32.0)
Age group
18-39 years 14.8 (13.8-15.9) 12.8 (11.6-14.1) 13.3 (10.7-16.6)
40-59 years 23.9 (22.8-25.0) 21.2 (19.8-22.6) 21.5 (18.6-24.7)
≥60 years 52.8 (51.0-54.5) 47.5 (45.2-49.8) 50.6 (45.7-55.5)
Place of residence
Western Federal States 26.7 (25.8-27.6) 24.0 (22.9-25.1) 25.8 (23.3-28.4)
Eastern Federal States 41.5 (39.6-43.5) 36.7 (34.3-39.2) 37.7 (32.6-43.0)
Target group
health care workers 30.5 (27.6-33.6) 27.3 (23.6-31.3) 25.8 (20.4-32.1)
chronically ill persons 43.3 (41.7-44.9) 39.8 (37.8-41.9) 41.0 (36.9-45.3)
non-target group 16.6 (15.8-17.5) 14.2 (13.2-15.3) 14.8 (12.5-17.5)
*Weighted data.
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tions in general’ (8.5%; 95% CI: 7.8-9.2).Factors associated with pandemic influenza
vaccine uptake
Results of univariate and multivariable analysis of factors po-
tentially associated with pandemic influenza vaccine uptake
are shown in Table 3. Having received a seasonal influenza
vaccination in the previous season (season 2008/09) was the
strongest independent predictor of pandemic influenza vac-
cination. However, this effect differed by age group and weFigure 1 Seasonal vaccination coverage by age group and target grotherefore included an interaction term in the final model.
Additionally, working as HCW, having a chronic disease,
high socioeconomic status, and being male were significantly
associated with higher uptake in multivariable analysis.Discussion
The aim of this study was to assess the uptake of sea-
sonal influenza vaccines in specific target groups for sea-
sons 2008/09 and 2009/10, as well as for pandemic
influenza vaccines during the pandemic season 2009/10
in Germany in the total adult population by using dataup, season 2009/10.
Figure 2 Trends in seasonal vaccine uptake in target groups in Germany for seasons 2007/08 − 2010/11 according to GEDA09 and
GEDA10 (filled symbols) and a follow-up sample of GEDA10 (empty symbols). 1 Data source: GEDA09 (n=15,552) [12]; 2 Data source:
GEDA10 (n=22,009); 3 Data source: GEDA10 (n=13,040); 4 Data source: GEDA follow-up survey (n=2,492).
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By using data from a smaller follow-up survey, our study
moreover provides the only so far available data on sea-
sonal influenza vaccination coverage in Germany for the
post-pandemic season 2010/11. Overall, only 8.8% of the
adult population in Germany followed the official
recommendation and received a vaccination against pan-
demic influenza in season 2009/10. The follow-up survey
revealed a decrease in seasonal influenza vaccine uptake
in the first post-pandemic season across all target groups
when compared to the pre-pandemic season 2008/09,
most prominent among HCW. With an average cover-
age of 50% in the elderly, 41% in the chronically ill, and
28% in HCW in seasons 2008/09 to 2010/11, the EU
goal of reaching a seasonal influenza vaccination cover-
age of at least 75% in the target groups [20] has not yet
been achieved in Germany.
Having received a seasonal influenza shot in the pre-
pandemic season was the strongest predictor for receiv-
ing pandemic influenza vaccination in our study. The
high correlation between seasonal and pandemic influ-
enza vaccine uptake highlights the significance of habit-
ual behaviour with regard to influenza vaccination
decisions. In addition and independent from this factor,
persons belonging to at least one of the recommended
target groups for seasonal influenza vaccination were
significantly more likely to receive a pandemic influenza
vaccination than persons not belonging to a target
group. Our results are broadly in line with the findings
of a prospective monitoring survey on pandemic influ-
enza vaccination in Germany [6] and two reviewsinvestigating determinants of pandemic vaccine uptake
[21,22]. Prior seasonal vaccination was not only found to
be positively associated with the intention to receive the
pandemic vaccination among adults in several industria-
lized countries (e.g. in the UK [23], France [24], Australia
[25], and the US [26]) but also with the actual receipt of
the vaccination (e.g. [6,27,28]). When developing vaccin-
ation strategies for future pandemic situations one should
therefore consider targeted strategies for enhancing cover-
age among those who do not fall within the target groups
for seasonal influenza vaccination and thus do not
regularly receive a seasonal influenza shot. A further
opportunity to enhance compliance with national
recommendations and therefore vaccination coverage in
a future pandemic situation could be to increase sea-
sonal vaccine uptake in the target groups. However,
major reasons for not being vaccinated were the per-
ception that vaccination was not necessary or not safe.
It can be assumed that both reasons will not be bar-
riers to high pandemic vaccine uptake in a future pan-
demic setting if the mortality is much higher than
during the 2009/10 pandemic.
A higher uptake of seasonal influenza vaccines in sea-
son 2009/10 was observed in the follow-up survey popu-
lation when compared to the total GEDA10 study
population in 2009/10. It is therefore very likely that the
point estimates for seasonal influenza vaccination cover-
age for the 2010/11 season, which were based on data
from the same follow-up survey, were also overestimated.
Taking into consideration that acceptance of seasonal in-
fluenza vaccination was higher in the follow-up survey
Table 3 Determinants of pandemic influenza vaccine uptake, Germany, season 2009/10
n# A(H1N1)pdm09 vaccination coverage; % (95%CI)# Odds Ratio (95%CI)#
univariate multivariable
Total 13,032 8.8 (8.2-9.5) - -
Sex
female 6,730 7.8 (7.1-8.7) 1ref 1ref
male 6,302 9.9 (8.9-10.9) 1.29 (1.14-1.45)** 1.36 (1.15-1.61)**
Vaccinated against seasonal influenza in season 2008/09
for agegroup 18–59 years
no 7,218 4.4 (3.8-4.9) 1ref 1ref
yes 1,784 22.9 (20.7-25.3) 6.54 (5.43-7.87)** 5.98 (4.96-7.20)**
for agegroup ≥60 years
no 1,925 1.9 (1.3-2.8) 1ref 1ref
yes 2,078 18.5 (16.1-21.1) 11.60 (7.51-17.01)** 4.76 (1.60-14.18)**
Place of residence
WFS 10,338 8.9 (8.2-9.6) 1ref n.s.
EFS 2,694 8.7 (7.3-10.3) 0.98 (0.84-1.14)
Socioeconomic Status
low 2,524 7.6 (6.1-9.5) 1ref 1ref
medium 7,777 8.0 (7.3-8.9) 1.06 (0.89-1.25) 1.01 (0.77-1.33)
high 2,688 12.2 (11.1-13.4) 1.69 (1.40-2.03)** 1.61 (1.23-2.11)**
Health care workers
no 687 8.4 (7.8-9.1) 1ref 1ref
yes 12,345 16.5 (13.9-19.6) 2.16 (1.75-2.67)** 2.30 (1.78-2.96)**
Underlying chronic disease
no 8,786 7.2 (6.6-7.9) 1ref 1ref
yes 4,246 12.2 (10.9-13.6) 1.79 (1.58-2.02)** 1.42 (1.19-1.69)**
#weighted data; * p<0.05; ** p<0.001; ref=reference category; n.s.= not significant; WFS=Western federal states, EFS=Eastern federal states.
p-value for interaction between agegroup*seasonal influenza vaccination status: 0.011.
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enza vaccine uptake in the recommended target groups
in Germany has decreased in the post-pandemic season
2010/11, not only in comparison to season 2008/09 but
also to the pandemic season 2009/10 (compare Figure 2,
empty symbols). Hence, our findings are discordant with
observations made in several other industrialised coun-
tries. For instance, seasonal influenza vaccination cover-
age in the UK remained stable between seasons 2009/10
and 2010/11 among at risk persons under 65 years of age
(51.6% vs. 50.4% vaccination coverage) as well as among
persons aged ≥65 years (72.4% vs. 72.8%) [29]. Among
high-risk persons aged 18–64 years living in the US, sea-
sonal influenza vaccine uptake was 46.2% in the pan-
demic and 46.7% in the post-pandemic season [30].
However, in both countries acceptance and uptake of
pandemic influenza vaccination was higher as compared
to Germany (UK: 37.6% vaccination coverage in clinical
risk groups [29]; US: 41.2% among all persons aged ≥6
month [31]). In France, despite the poor uptake of pan-
demic influenza vaccines (11.1%), an increase in seasonal
influenza vaccine uptake was observed in the post-pandemic season among persons aged ≥65 years with
underlying chronic conditions (62.6% in season 2009/10
[27] vs. 71.0% in season 2010/11 [32]). In the upcoming
years, the uptake of seasonal influenza vaccines should be
carefully monitored in Germany in all target groups to
identify if this trend continues. Especially the strong
decrease in vaccination coverage among HCW is of con-
cern, and communication activities should be strength-
ened especially for this target group not only to achieve
individual protection of this target group but also to pro-
tect vulnerable patients managed by HCW.
In our study ‘fear of side effects’ was found to be
the most frequently stated reason for rejecting pan-
demic vaccination, thereby confirming findings of 13
smaller consecutive surveys carried out during the
pandemic in Germany [33]. Conversely, believing that
the pandemic vaccine is safe was significantly asso-
ciated with the receipt of the pandemic vaccine in
many countries worldwide [21]. Appropriate addres-
sing of vaccine safety concerns by public health au-
thorities may be an important factor to maintain
public trust in national vaccination recommendations
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pandemic situations [22,33].
In our study, 8.5% of those who did not receive a pan-
demic influenza vaccination stated that they reject vacci-
nations in general. This translates into a proportion of
7.7% for the total study population. Little is known
about the exact proportion of vaccination opponents
among the general adult population in Germany. In a re-
cent survey performed by the German Federal Centre
for Health Education (BZgA) among 3,002 parents of
children aged 0–13 years, 35% stated that they reject
particular vaccinations for their children, but only 1% of
parents reject vaccinations in general [34]. Since our
study did not focus on the general rejection of vaccina-
tions in the population, we did not ask further detailed
questions related to this topic to verify this attitude and
the underlying reasons. Therefore, this figure must be
interpreted with caution.
Our study has some limitations that need to be
acknowledged. Calculation of influenza vaccination
coverage was based on self-reported vaccination status
and may therefore be prone to recall problems. However,
it was shown in several studies that self-report of influ-
enza vaccination status has an adequate degree of valid-
ity [35,36]. Furthermore, the response rate in GEDA10
was comparatively low at 29%. However, it should be
noted that the chosen method of calculating the re-
sponse rate (namely Response Rate 3 as defined by
AAPOR [18]) is a very conservative approach and that
our response rate is comparable to studies using the
same approach (e.g. CDC-Behavioral Risk Factor Surveil-
lance Rates Report [37]). Finally, it cannot be ruled out
that other reasons than the controversial discussions on
the pandemic vaccination have also contributed to the
observed drop in seasonal influenza vaccination coverage
in 2010/11.
Conclusion
In conclusion, poor compliance with official vaccination
recommendation resulting in low uptake of pandemic
influenza vaccines during the pandemic season 2009/10
suggests that public communication strategies and vac-
cination campaigns during the influenza A(H1N1)
pdm09 pandemic in Germany were not successful. In
addition, our results raise concerns that controversial
discussions about the safety and necessity of pandemic
influenza vaccines may have contributed to decreased
seasonal influenza vaccine uptake in the first post-
pandemic season. It is therefore crucial to develop con-
certed communication strategies based on the lessons
learned from the 2009/10 influenza pandemic and to in-
clude them in the national pandemic preparedness plan.
This should be done, not only with respect to a compe-
tent handling of pandemic situations but also to avoid adecrease in the acceptance of vaccinations in general. In
this respect, communication strategies and different
modes of communication to specific target groups
should be evaluated and implemented already in non-
crisis situations, to be enhanced during a pandemic in-
fluenza situation or other public health crisis. This is of
particular importance, since seasonal influenza vaccine
uptake in the recommended target groups in Germany
stagnated at a low level since 2005 [38] and does by far
not meet the EU goal of 75% [20]. Further studies should
be conducted to monitor the trends of seasonal influ-
enza vaccine uptake in Germany in the specific target
groups including pregnant women (which is a target
group for seasonal influenza vaccination since 2010) and
to precisely identify barriers to influenza vaccination in
the upcoming years which might differ from the pan-
demic and the first post-pandemic season. This informa-
tion would be crucial to guide public health authorities
in developing more effective communication strategies
for seasonal influenza vaccination tailored to specific tar-
get groups.
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